Company intelligence / Profile preview

Amplifica Studio

San Diego, California, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Other

Overview

First-in-human clinical trial of AMP-303 demonstrated safety and promising efficacy, with over 15% increase in thicker/coarser hair at day 60 post-treatment in men aged 18–45 with androgenetic alopecia. Results were presented at major dermatology meetings and published in peer-reviewed journals. Additional programs are preclinical.

Therapeutic areas: Dermatology
Modalities: ProteinSmall molecule
Industry: Biotech

Partnerships

Exclusive licensing agreement for early-stage protein asset to expand pipeline

Beyond the preview

Go deeper on Amplifica Studio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amplifica Studio.

Explore the full profile